



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	AFT Pharmaceuticals Limited
Date this disclosure made:	3-Jul-25
Date of last disclosure:	27-Jun-25

#### Director or senior manager giving disclosure

Full name(s):	Hartley Campbell Atkinson
Name of listed issuer:	AFT Pharmaceuticals Limited (AFT)
Name of related body corporate (if applicable):	Not applicable
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Fully paid ordinary shares in AFT
Nature of the affected relevant interest(s):	Power (jointly with Colin McKay as trustees of the Atkinson Family Trust) to control the exercise of the right to vote attached to, and the power (jointly with Colin McKay as trustees of the Atkinson Family Trust) to control the disposal of, ordinary shares in AFT held by the Atkinson Family Trust

#### For that relevant interest-

Number held in class before acquisition or disposal:	72,059,496
Number held in class after acquisition or disposal:	72,259,496
Current registered holder(s):	Hartley Campbell Atkinson and Colin McKay as trustees of the Atkinson Family Trust
Registered holder(s) once transfers are registered:	Not applicable

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	Not applicable
Class of underlying financial products:	Not applicable

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	Not applicable
A statement as to whether the derivative is cash settled or physically settled:	Not applicable
Maturity date of the derivative (if any):	Not applicable
Expiry date of the derivative(if any):	Not applicable
The price specified in the terms of the derivative (if any):	Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	Not applicable

#### For that derivative,-

Parties to the derivative:	Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	Not applicable

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	3
---	---

**Details of transactions requiring disclosure-**

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:
Number of financial products to which the transaction related:
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest,-</i>
Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest,-</i>
Type of derivative:

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Jun 30, Jly 1 and Jly 2 2025
On-market purchase of ordinary shares
Not applicable
200,000 shares at an average of \$2.83 per share / \$566,000
200,000 ordinary shares

No
Not applicable
Not applicable

Fully paid ordinary shares in AFT
Joint registered holder and beneficial owner

867,826
Hartley Campbell Atkinson and Colin McKay (as trustees of the Atkinson Family Trust) to control the exercise of the right to vote attached to, and the power (jointly with Colin McKay as trustees of the Atkinson Family Trust) to control the disposal of, ordinary shares in AFT held by HAMA Holdings Limited as bare trustee for the Atkinson Family Trust

Not applicable
----------------

Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable

July 3 2025
Malcolm Tubby - CFO